Raymond James Financial
TXG icon

Raymond James Financial’s 10x Genomics TXG Stock Holding History

Raymond James Financial’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92M Buy
102,180
+87,709
+606% +$2.3M ﹤0.01% 2949
2026
Q1 		$307K Buy
+14,471
New +$289K ﹤0.01% 4647
2025
Q4 		– Sell
-13,264
Closed -$155K – 5338
2025
Q3 		$155K Sell
13,264
-10,001
-43% -$130K ﹤0.01% 4678
2025
Q2 		$269K Sell
23,265
-8,230
-26% -$75K ﹤0.01% 4360
2025
Q1 		$275K Buy
31,495
+1,490
+5% +$18.8K ﹤0.01% 4266
2024
Q4 		$431K Buy
+30,005
New +$473K ﹤0.01% 3992

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial's TXG Position: Q2 2026 in Review

Raymond James Financial increased its 10x Genomics (TXG) stake by 606% in Q2 2026, buying an estimated $2.3M and bringing the position to 102,180 shares worth $3.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

Raymond James Financial first reported a position in TXG in Q4 2024 and has held it in 6 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Raymond James Financial held 102,180 shares of 10x Genomics worth $3.92M as of Q2 2026.
  • Raymond James Financial bought 87,709 10x Genomics shares in Q2 2026, an estimated $2.3M.
  • 10x Genomics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2949 holding.
  • Raymond James Financial first reported a position in 10x Genomics in Q4 2024 and has held it in 6 quarters since.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.